Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Juvenescence Raises $100M To Advance Anti-Aging Programs

Executive Summary

The financing, which brings the total raised by Juvenescence to $165m, comes as longevity R&D programs supported by the company move towards human testing.

You may also be interested in...



Anti-Aging Firm Unity Stumbles At First Major Hurdle

Unity is set to drop its lead product based on its senescent cell science as it fails in a Phase II study in osteoarthritis of the knee. Focus switches to ophthalmic product.

Finance Watch: Chinook Debuts With $65m For Precision Kidney Disease Medicines

Private Company Edition: The start-up intends to take multiple drug candidates into the clinic by 2021. Also, Graybug Vision raises an $80m series B and Finch closes a $53m series C.

Executives On The Move: Candel Therapeutics, Technoderma Medicines And More

Recent executive changes in the industry include C-suite moves at Bluebird Bio and Jounce Therapeutics. Meanwhile, new directors were appointed at Candel Therapeutics and Technoderma Medicines. 

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC125724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel